Providing information to the drug discovery sector

Dedicated to Drug Discovery

LeadDiscovery was founded in 1998 by life scientists to expedite drug discovery and pharmaceutical development. Based on a solid background of experience from within the pharmaceutical research and development sector our aim is to help companies optimize drug discovery and product pipelines through the identification of breaking research and the in depth and expert evaluation of selected therapeutic areas.

At the same time we provide a showcase for pharmaceutical, biotechnology and academic organizations wishing to increase the exposure of their research to the drug development community.

We support the drug discovery and pharmaceutical development community through three key services: DailyUpdates, UpdatesPlus and PharmaReports

Todays drug discovery and development headlines from across the DailyUpdates network

6th August 2016

Drug Development News: FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy - See more at: http://www.merck.com/newsroom/#News

Headlined Journal Article: Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

Clinical Trials: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma

Today’s Featured Pharmaceutical Report: Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022

Pharmaceutical Training Courses and Meetings: No current events.


LeadDiscovery recommends ClusterMed for faster discovery and automatic organization of PubMed results into categories


PharmaReports: LeadDiscovery offers in depth pharmaceutical reports on selected areas of the pharmaceutical and biotech sector. For a full list of our featured market research reports and pipeline analyses click here





For Inhibitor, Antibody, siRNA, Peptide

- Kinase Inhibitors
- Olaparib
- Imatinib
- Bortezomib
- Screening Library
- Parp Inhibitor
& MDV 3100 Inhibitors